Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel
NASDAQ:FEED

Nanovibronix Q1 2026 Earnings Report

Nanovibronix logo
$0.36 -0.02 (-6.34%)
Closing price 04:00 PM Eastern
Extended Trading
$0.37 +0.01 (+2.85%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nanovibronix EPS Results

Actual EPS
-$6.88
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nanovibronix Revenue Results

Actual Revenue
$0.65 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nanovibronix Announcement Details

Quarter
Q1 2026
Date
5/18/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nanovibronix Earnings Headlines

ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3332126/0/en/ENvue-Medical-Deploys-Additional-Navigation-Platform-with-Existing-Customer-A-Leading-North-Texas-Medical-Center.html
ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327653/0/en/envue-medical-appoints-chairman-of-the-board-and-new-directors-bringing-clinical-ai-governance-and-capital-markets-expertise-to-navigation-platform.html
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.tc pixel
July 27 at 1:00 AM  |  Chaikin Analytics (Ad)
ENvue Medical Unveils Its First Robotic-Assisted, Artificial Intelligence, Feeding Tube Automation Tool
July 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/09/3324896/0/en/envue-medical-unveils-its-first-robotic-assisted-artificial-intelligence-feeding-tube-automation-tool.html
Brazil Potash Awards Front End Engineering Design (FEED) Contract For Mine Shafts and Underground Development to WSP UK Ltd., with Redpath Deilmann Mining Inc. as Subconsultants, Completing Full-Project FEED Coverage at Autazes
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313300/0/en/brazil-potash-awards-front-end-engineering-design-feed-contract-for-mine-shafts-and-underground-development-to-wsp-uk-ltd-with-redpath-deilmann-mining-inc-as-subconsultants-complet.html
Ohmium and Hynfra Sign Master Cooperation Agreement to Advance Large-Scale Green Hydrogen Projects in the Middle East and Africa
June 17, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260617825133/en/ohmium-and-hynfra-sign-master-cooperation-agreement-to-advance-large-scale-green-hydrogen-projects-in-the-middle-east-and-africa/
See More Nanovibronix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanovibronix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanovibronix and other key companies, straight to your email.

About Nanovibronix

Nanovibronix (NASDAQ:FEED) (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company's product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies. Its offerings are intended to be user‑friendly, portable and suitable for repeated application, which supports adoption in ambulatory care and self‑care environments. Nanovibronix emphasizes clinical research and device development to validate therapeutic effects and to support regulatory and reimbursement discussions in the markets it serves.

As a publicly traded entity on the NASDAQ exchange under the ticker FEED, Nanovibronix engages in the full product lifecycle from research and development through manufacturing, regulatory engagement and distribution. The company has historically sought to expand market access through clinical collaborations, distribution partnerships and targeted commercialization initiatives. Detailed, current information about specific products, regulatory clearances, market geographies or executive leadership was not available in the material used to prepare this summary.

View Nanovibronix Profile
Earnings Tools